Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

Annals of Hematology

Volumn 92, Issue 6, 2013, Pages 771-775

  Hernández Boluda, Juan Carlos ^a   Pereira, Arturo ^b   Cervantes, Francisco ^c   Gómez, Montse ^a   Arellano Rodrigo, Eduardo ^b   Alvarez Larrán, Alberto ^d   Ferrer Marín, Francisca ^e   Kerguelen, Ana ^f   Márquez, José Antonio ^g   Antelo, María Luisa ^h   Besses, Carles ^d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL MORALES MESEGUER   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL DE BASURTO   (Spain)

^h Universidad Pública de Navarra   (Spain)

Author keywords

Anagrelide; Essential thrombocythemia; Response criteria; Treatment

Indexed keywords

ANAGRELIDE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLEEDING; CLINICAL EVALUATION; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTHEMIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; INTERFERONS; INTERNATIONAL AGENCIES; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; ORGAN SIZE; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PROGNOSIS; QUINAZOLINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SPAIN; SPLEEN; SURVIVAL ANALYSIS; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877733141     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1683-7     Document Type: Article

References (11)

1. Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467-1473
2. Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21(24):4642-4649
3. Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041-6051
4. Barosi G, Birgegard G, Finazzi G et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113(20):4829-4833
5. Hernandez-Boluda JC, Alvarez-Larran A, Gomez M et al (2011) Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 152(1):81-88
6. Alvarez-Larran A, Pereira A, Cervantes F et al (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119(6):1363-1369
7. Carobbio A, Finazzi G, Antonioli E et al (2010) Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood 116(7):1051-1055
8. Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4):1092-1097
9. Harrison CN, Campbell PJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33-45
10. Tang SS, Frojmovic MM (1980) Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3′, 5′-adenosine monophosphate phosphodiesterase. J Lab Clin Med 95(2):241-257
11. Barosi G, Tefferi A, Barbui T (2012) Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? Leukemia 26(5):1148-1149